Nutreco
VC Fund
Amersfoort, The Netherlands
Nutreco is a global leader in animal nutrition and aquafeed. Our advanced nutritional solutions are at the origin of food for millions of consumers worldwide.Quality, innovation and sustainability are guiding principles, embedded in the Nutreco culture from research and raw material procurement to products and services for livestock farming andaquaculture. Experience across 100 years brings Nutreco a rich heritage of knowledge and expertise for building its future.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Nutreco invests in
Stages Nutreco invests in
Countries Nutreco invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Kees Dekker
|
|||
|
Laurent Genet
|
|||
Panagiotis Vlachogiannis
|
|||
Susanne Wiegel
|
|||
Investment Focus
Industry
- Biotechnology 7 (44%)
- AgTech 3 (19%)
- Agriculture 3 (19%)
- Food and Beverage 3 (19%)
- Farming 2 (13%)
Stage
- Series B 4 (25%)
- Series A 3 (19%)
- Venture - Series Unknown 3 (19%)
- Corporate Round 2 (13%)
- Series C 1 (6%)
Country
- United States 3 (19%)
- India 2 (13%)
- United Kingdom 2 (13%)
- Israel 1 (6%)
- Poland 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Kees Dekker
Chief Financial Officer & member of the executive board
|
Chief Financial Officer & member of the executive board | Total investments: 0 | Find email | |
|
Laurent Genet
Chief Strategy Officer & Member Executive Committee
|
Chief Strategy Officer & Member Executive Committee | Total investments: 0 | Find email | |
|
Panagiotis Vlachogiannis
Junior Specialist Cell Nutrition
|
Junior Specialist Cell Nutrition | Total investments: 0 | Find email | |
|
Susanne Wiegel
Investment Manager Alternative Proteins
|
Investment Manager Alternative Proteins | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BiomEdit
|
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of themicrobiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics. | $18.4M / Series B / Jul 15, 2025 | |
LAXEY
|
LAXEY specializes in sustainable land-based aquaculture and the development of fish farming facilities. | $42.6M / Venture - Series Unknown / Apr 22, 2024 | |
ViAqua Therapeutics
|
ViAqua Therapeutics Ltd develops drugs and therapeutics for aquaculture. The company was founded in 2014 and is based in Israel.ViAqua Therapeutics is developing the first orally administered treatment for aquaculture.The Company’s management bring a broad range of business development, technology development, management, and industrial biotechexperience. | $8.3M / Venture - Series Unknown / Sep 05, 2023 | |
|
BiomEdit
|
BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of themicrobiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics. | $4M / Series A / Feb 18, 2023 | |
Roslin Technologies
|
Roslin Tech is on a mission to improve protein production through disruptive technologies. Our core capability is in animal stem cells; we have developed the world’s perpetually self-renewing, pluripotent stem cells for animals (iPS cells) which will accelerate the development of cultivated meat for the consumer market. | $12.3M / Series A / Nov 03, 2022 | |
Stellapps
|
Stellapps designs dairy management software applications that leverage the power of technology to improve dairy supply chain parameters. The company's applications leverage the Internet of Things (IoT), big data, cloud, mobility and data analytics to improve agri-supply chain parameters, including milk production, milk procurement, cold chainanimal insurance and farmer payments, enabling dairy farms, dairy farmers and cooperatives to maximize profits while minimizing effort. | $18M / Series C / Sep 15, 2021 | |
Proteon Pharmaceuticals
|
PROTEON uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. We have developed a platform to develop and deliver bacteriophages for animal health solutions. Our pipeline includes solutions to prophylactically improveperformance and food safety in poultry, as well as important prevent economically important bacterial diseases in aquaculture and dairy. | $24.6M / Venture - Series Unknown / Aug 10, 2021 | |
Proteon Therapeutics
|
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $24.6M / Post-IPO Equity / Aug 10, 2021 | |
ENOUGH
|
ENOUGH is a technology spin-out company from the University of Strathclyde established to develop and commercialise novel patented technology which transforms the production economics for the meat-free food product mycoprotein by integrating the production within existing bio-refinery operations producing bio-ethanol and animal feed (DDGS). Thisgives integrated fermentation production of Food, Fuel and Feed. | $49.9M / Series B / Jun 20, 2021 | |
|
ViAqua Therapeutics
|
ViAqua Therapeutics Ltd develops drugs and therapeutics for aquaculture. The company was founded in 2014 and is based in Israel.ViAqua Therapeutics is developing the first orally administered treatment for aquaculture.The Company’s management bring a broad range of business development, technology development, management, and industrial biotechexperience. | $4.3M / Venture - Series Unknown / Jun 09, 2021 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Nutreco invest in?
Nutreco invests primarily in Biotechnology, AgTech and Agriculture startups, most often at Series B and Series A stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nutreco?
Public channels for Nutreco include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nutreco?
The team at Nutreco includes Kees Dekker (Chief Financial Officer & member of the executive board), Laurent Genet (Chief Strategy Officer & Member Executive Committee) and Panagiotis Vlachogiannis (Junior Specialist Cell Nutrition). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
